Pfizer gives up, page-19

Interesting comment. I suspect they looked at the financials and panicked somewhat. What the financials did not disclose is the (approx.) $0.9 Mil. Tax rebate due to ACW as a result of the expenditure incurred in the first half. (as a side issue, the reduction in the company tax rate has cost ACW approx. $150K in tax rebate due to the rate going from 30 c./$ to 25 c/$). Without the tax rebate, the financials could indicate that ACW may end up short of funds in the 1H 2019y. With the rebate for the full year due in H2 2018y (of approx. $1.8 Mil.), then the company remains fully funded for the remainder of the trial.